Etoricoxib Versus Gabapentin for Knee Arthroscopy

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine that when administered as part of a multimodal analgesic regimen, use of the new COX-2 antagonist etoricoxib (120 mg/day, per os) is more effective in improving postoperative pain management after knee arthroscopy than gabapentin (1.2 g/day, per os).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Meir Medical Center
• Treatments: Etoricoxib; Gabapentin; gamma-Aminobutyric Acid

Criteria

Inclusion Criteria:

• Elective ambulatory knee arthroscopy

Exclusion Criteria:

• History of clinically-significant cardiovascular,pulmonary,hepatic,renal, neurologic, psychiatric or metabolic disease

• Patients chronically receiving pain killers